Close Menu
newzz.net
    Facebook X (Twitter) Instagram
    Trending
    • After months with the Galaxy Watch 9, I have 3 favorite features
    • Editorial. COP out
    • New Audubon Report Reveals Population Trends for Birds in Latin America and the Caribbean
    • 15 key cases from Northern Ireland's courts this week
    • Lefant M210 Omni Combines 20,000Pa Suction and Fresh-Water Roller Mopping in an Ultra-Compact Design
    • UltraTech Cement: Volume Expansion To Continue
    • Alastair Campbell’s diary: The old are letting down Britain’s young – so let’s build a youth club for every postcode
    • Saver’s Match Overview (Replaces the Saver’s Credit in 2027)
    newzz.net
    Sunday, November 15
    • Home
    • Top Stories
    • Technology
    • Business
    • Politics
    • Health
    • Loans
    • Interest Rates
    • Mortgage
    • Entertainment & Arts
    • Science & Environment
    • Smart Solutions
    newzz.net
    You are at:Home»Business»US proposal to halve biosimilar development costs for Biocon, top exec says
    Business

    US proposal to halve biosimilar development costs for Biocon, top exec says

    Editorial TeamBy Editorial TeamNovember 13, 2025No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    US proposal to halve biosimilar development costs for Biocon, top exec says

    The firm’s revenue from biosimilars grew 25% in the
latest quarter.

    The firm’s revenue from biosimilars grew 25% in the
    latest quarter.
    | Photo Credit:
    DHIRAJ SINGH

    Biocon expects a 50% drop in costs for
    developing complex biosimilars as the United States has proposed
    to ease clinical testing for the drugs that make up more than
    60% of its revenue, a top executive said on Wednesday.

    Biosimilars are copies of costlier biological drugs used
    to treat major illnesses such as cancer, rheumatoid arthritis,
    psoriasis and diabetes. The U.S. Food and Drug Administration
    last month proposed to simplify drug testing by lowering the
    requirement for large comparative clinical efficacy trials.

    Biocon, which aims to cumulatively launch 20 biosimilars by
    2030, is focusing on upcoming launches in the key markets of
    U.S. and Europe, Shreehas Tambe, CEO of Biocon Biologics, a unit
    of Biocon, said in an interview.

    “You can do more because it’s (FDA’s draft proposal) going
    to halve the cost of development … you can develop them
    (biosimilars) and bring them to patients faster and make it more
    affordable.”

    Biocon, which has seven of its biosimilars in the commercial
    market in the U.S., is looking to launch two more in the next
    six months. The company’s oncology biosimilar medicines have a
    fourth of the U.S. market share and will benefit from the lower
    development cost, Tambe said.

    The firm’s revenue from biosimilars grew 25% in the
    latest quarter.

    Biocon is also looking to expand its generics segment with
    the launch of weight-loss drugs to drive future growth, the
    company had said earlier.

    Published on November 13, 2025

    Biocon biosimilar costs Development exec halve proposal Top
    Previous Article468. Starmer in Crisis: Sabotage From Within? (Question Time)
    Next Article Galaxy Z TriFold leak reveals massive screen, impressive specs, and unusual design quirk
    Editorial Team
    • Website

    Related Posts

    Editorial. COP out

    UltraTech Cement: Volume Expansion To Continue

    Yes Bank seeks Supreme Court review of ₹8,415-crore AT-1 bond write-off ruling

    Comments are closed.

    • Facebook
    • Twitter
    • Instagram
    • Pinterest
    Don't Miss

    After months with the Galaxy Watch 9, I have 3 favorite features

    Editorial. COP out

    New Audubon Report Reveals Population Trends for Birds in Latin America and the Caribbean

    15 key cases from Northern Ireland's courts this week

    About

    Welcome to Newzz.net, your trusted source for timely, accurate, and insightful news from around the world. We are dedicated to delivering the latest updates and in-depth analysis across a wide range of topics, ensuring our readers stay informed, empowered, and engaged.
    We're social, connect with us:

    Popular Posts

    After months with the Galaxy Watch 9, I have 3 favorite features

    November 15, 2026

    Editorial. COP out

    November 15, 2026

    New Audubon Report Reveals Population Trends for Birds in Latin America and the Caribbean

    November 15, 2026
    Categories
    • Business
    • Entertainment & Arts
    • Health
    • Interest Rates
    • Loans
    • Mortgage
    • Politics
    • Science & Environment
    • Smart Solutions
    • Technology
    • Top Stories
    Copyright © 2026. newzz.net Designed by Webwazirds7.
    • About Us
    • Privacy Policy
    • Terms and Conditions
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.